Nonavalent HPV vaccine

ApprovedVaccine

XXiamen University

Nonavalent HPV vaccine is one of 37 biologic programs targeting Immunology. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ImmunologyActive, not recruiting

PapillomaActive, not recruiting

ImmunologyApproved

Active, not recruiting

PapillomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

150 competitors in Papilloma

#DrugCompanyPhaseTrials

Cervarix

GSK

Phase 3

9 2

GSK 257049

GSK

Phase 3

6 3

Comparator: Pbo

Merck & Co.

Phase 3

3 4

Gardasil

Merck & Co.

Phase 3

11 5

Havrix

GSK

Phase 3

1 6

Engerix-B

GSK

Phase 3

1 7

Taxol

Teva

Phase 2

2 8

Tecentriq

Roche

Phase 2

1 9

Boostrix

GSK

Phase 3

1 10

HPV Vaccine

SShanghai Zerun Biotechnology Co.,Ltd

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Not yet recruiting

Vaccination

NCT07303751

Phase 3Active, not recruiting

HPV Vaccine

NCT02834637

Q3 2027

ApprovedActive, not recruiting

Immunology

NCT07493460

Q4 2027

Phase 3Active, not recruiting

Papilloma

NCT04537156

Q1 2028

Post-ApprovalRecruiting

HPV Vaccine

NCT05495906

Clinical

Trials by Indication[1]

HPV Vaccine2 trials

A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living With HIV

Recruiting·UUniversity of British Columbia·Phase 4·NCT05495906·275 enrolled

A Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls

Active, not recruiting·LLondon School of Hygiene and Tropical Medicine·Phase 3·NCT02834637·930 enrolled

Papilloma1 trial

Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)

Active, not recruiting·XXiamen University·Phase 3·NCT04537156·9,327 enrolled

Vaccination1 trial

Study Assessing Reduced HPV Infectivity and Transmission in HPV-Positive Women Following Vaccination With 9vHPV

Not yet recruiting·IInstitut d'Investigació Biomèdica de Bellvitge·Phase 2·NCT07303751·80 enrolled

Immunology1 trial

Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines

Active, not recruiting·WWashington University School of Medicine·Approved·NCT07493460·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Nonavalent HPV vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nonavalent HPV vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nonavalent HPV vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Xiamen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Approved[1]
Company: XXiamen University

Nonavalent HPV vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2027

Q4 2027

Q1 2028

Trials by Indication[1]

HPV Vaccine2 trials

Papilloma1 trial

Vaccination1 trial

Immunology1 trial

References

Drug Info

Quick Facts

Related News